Article Text

Download PDFPDF
Extrapolation or controlled trials in paediatrics: the current dilemma

Statistics from Altmetric.com

Footnotes

  • Contributors NR drafted the first version, which was subsequently revised by HIB, DJL and AM.

  • Competing interests NR has received grants from BMS, Hoffman-La Roche, Janssen, Novartis, Pfizer, Sobi during the conduct of the study, and personal fees and speaker honorarium from AbbVie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer, Bristol Myers Squibb, Celgene, Eli-Lilly, EMD Serono, Gilead Sciences, Janssen, Medimmune, Novartis, Pfizer, R-Pharm, Roche, Sanofi, Servier and Takeda. HIB reports grants/research support from National Institutes of Health, NIAMS; HIB has also received consultancy fees from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen; speaker bureaus from Genentech. DJL reports grants/research support from National Institutes of Health, NIAMS; DJL has also received consultancy fees from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen, and speaker bureaus from Genentech. Starting 1 March 2016 AM became the Scientific Director of the G Gaslini Hospital; therefore his role does not allow to render private consultancies resulting in personal income. AM has performed consultancy activities on behalf of the Gaslini Institute for the following companies: AbbVie, Boehringer, Novartis and R-Pharm. The money received for these activities are directly transferred to the Gaslini Institute’s bank account.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles